Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, nonrandomized multicenter study designed to evaluate time to progression
and response proportion of patients with advanced or metastatic transitional cell carcinoma
of bladder receiving 6 cycles of gemcitabine, carboplatin and sorafenib and then maintenance
sorafenib.